Hathal Haddad: Brachytherapy Boost Shows Compelling Long-term Evidence in Prostate Cancer
Hathal Haddad, Head of Interventional Radiotherapy Unit of the Department of Radiation Oncology at Tübingen University Hospital, shared a post on LinkedIn about a paper by Peter J. Hoskin et al. published in Radiotherapy and Oncology:
“HDR-Brachytherapy boost and EBRT are superior to EBRT alone for treatment of prostate cancer.
The results of a randomized phase-III trial (Radiother Oncol, 2021) provide compelling long-term evidence for the use of high-dose-rate brachytherapy (HDR-BT) boost in combination with external beam radiotherapy (EBRT) for localized prostate cancer.
Key Findings:
- EBRT + HDR-BT significantly improved relapse-free survival (48% at 12 years vs. 27% with EBRT alone, p = 0.008).
- Median time to relapse was nearly 5 years longer with the HDR-BT boost.
- No significant increase in severe late urinary or bowel toxicity was observed between the two arms.
These findings highlight the long-term efficacy and safety of HDR brachytherapy as an integral component in prostate cancer treatment strategies.”
Title: Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results
Authors: Peter J. Hoskin, Ana M. Rojas, Peter J. Ostler, Linda Bryant, Gerry J. Lowe.
Read the Full Article on Radiotherapy and Oncology.
Read OncoDaily’s article on “Brachytherapy for Prostate Cancer: Types, Success Rate, Side Effects and More“.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023